Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
21
URGN Quote, Financials, Valuation and Earnings
Last price:
$23.00
Seasonality move
:
-2.48%
Day range:
$22.89 - $23.71
52-week range:
$3.42 - $30.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.35x
P/B ratio:
16.41x
Volume:
250.9K
Avg. volume:
946.1K
1-year change:
108.61%
Market cap:
$1.1B
Revenue:
$90.4M
EPS (TTM):
-$3.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
URGN
UroGen Pharma Ltd.
|
$43.7M | -$0.51 | 68.74% | -38.75% | $35.25 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.54 | -5.28% | -4.28% | $182.07 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$198K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
MGTX
MeiraGTx Holdings Plc
|
$1.8M | -$0.63 | -81.58% | -23.36% | $26.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
URGN
UroGen Pharma Ltd.
|
$23.03 | $35.25 | $1.1B | -- | $0.00 | 0% | 11.35x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
BIIB
Biogen, Inc.
|
$177.08 | $182.07 | $26B | 16.15x | $0.00 | 0% | 2.68x |
|
CVM
CEL-SCI Corp.
|
$4.71 | $42.50 | $14.3M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
MGTX
MeiraGTx Holdings Plc
|
$7.97 | $26.88 | $641.5M | -- | $0.00 | 0% | 23.18x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
URGN
UroGen Pharma Ltd.
|
894.17% | 4.259 | 13.92% | 3.51x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
MGTX
MeiraGTx Holdings Plc
|
185.38% | 0.506 | 13.3% | 0.12x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
URGN
UroGen Pharma Ltd.
|
$24.2M | -$27.4M | -209.52% | -- | -99.65% | -$47.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
MGTX
MeiraGTx Holdings Plc
|
-$3.1M | -$46.1M | -145.42% | -530.25% | -11231.95% | -$12.8M |
UroGen Pharma Ltd. vs. Competitors
-
Which has Higher Returns URGN or AIM?
AIM ImmunoTech has a net margin of -121.34% compared to UroGen Pharma Ltd.'s net margin of -10571.43%. UroGen Pharma Ltd.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital URGNUroGen Pharma Ltd.88.07% -$0.69 $14.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About URGN or AIM?
UroGen Pharma Ltd. has a consensus price target of $35.25, signalling upside risk potential of 53.06%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than UroGen Pharma Ltd., analysts believe AIM ImmunoTech is more attractive than UroGen Pharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings URGNUroGen Pharma Ltd.6 1 0 AIMAIM ImmunoTech1 0 0 -
Is URGN or AIM More Risky?
UroGen Pharma Ltd. has a beta of 1.214, which suggesting that the stock is 21.395% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock URGN or AIM?
UroGen Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma Ltd. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios URGN or AIM?
UroGen Pharma Ltd. quarterly revenues are $27.5M, which are larger than AIM ImmunoTech quarterly revenues of $35K. UroGen Pharma Ltd.'s net income of -$33.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, UroGen Pharma Ltd.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma Ltd. is 11.35x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income URGNUroGen Pharma Ltd.11.35x -- $27.5M -$33.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns URGN or BIIB?
Biogen, Inc. has a net margin of -121.34% compared to UroGen Pharma Ltd.'s net margin of 19%. UroGen Pharma Ltd.'s return on equity of -- beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital URGNUroGen Pharma Ltd.88.07% -$0.69 $14.5M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About URGN or BIIB?
UroGen Pharma Ltd. has a consensus price target of $35.25, signalling upside risk potential of 53.06%. On the other hand Biogen, Inc. has an analysts' consensus of $182.07 which suggests that it could grow by 2.82%. Given that UroGen Pharma Ltd. has higher upside potential than Biogen, Inc., analysts believe UroGen Pharma Ltd. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings URGNUroGen Pharma Ltd.6 1 0 BIIBBiogen, Inc.14 18 1 -
Is URGN or BIIB More Risky?
UroGen Pharma Ltd. has a beta of 1.214, which suggesting that the stock is 21.395% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock URGN or BIIB?
UroGen Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma Ltd. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios URGN or BIIB?
UroGen Pharma Ltd. quarterly revenues are $27.5M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. UroGen Pharma Ltd.'s net income of -$33.3M is lower than Biogen, Inc.'s net income of $466.5M. Notably, UroGen Pharma Ltd.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma Ltd. is 11.35x versus 2.68x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income URGNUroGen Pharma Ltd.11.35x -- $27.5M -$33.3M BIIBBiogen, Inc.2.68x 16.15x $2.5B $466.5M
-
Which has Higher Returns URGN or CVM?
CEL-SCI Corp. has a net margin of -121.34% compared to UroGen Pharma Ltd.'s net margin of --. UroGen Pharma Ltd.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital URGNUroGen Pharma Ltd.88.07% -$0.69 $14.5M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About URGN or CVM?
UroGen Pharma Ltd. has a consensus price target of $35.25, signalling upside risk potential of 53.06%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 802.34%. Given that CEL-SCI Corp. has higher upside potential than UroGen Pharma Ltd., analysts believe CEL-SCI Corp. is more attractive than UroGen Pharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings URGNUroGen Pharma Ltd.6 1 0 CVMCEL-SCI Corp.1 0 0 -
Is URGN or CVM More Risky?
UroGen Pharma Ltd. has a beta of 1.214, which suggesting that the stock is 21.395% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock URGN or CVM?
UroGen Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma Ltd. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios URGN or CVM?
UroGen Pharma Ltd. quarterly revenues are $27.5M, which are larger than CEL-SCI Corp. quarterly revenues of --. UroGen Pharma Ltd.'s net income of -$33.3M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, UroGen Pharma Ltd.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma Ltd. is 11.35x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income URGNUroGen Pharma Ltd.11.35x -- $27.5M -$33.3M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns URGN or IGC?
IGC Pharma, Inc. has a net margin of -121.34% compared to UroGen Pharma Ltd.'s net margin of -953.4%. UroGen Pharma Ltd.'s return on equity of -- beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital URGNUroGen Pharma Ltd.88.07% -$0.69 $14.5M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About URGN or IGC?
UroGen Pharma Ltd. has a consensus price target of $35.25, signalling upside risk potential of 53.06%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1192.1%. Given that IGC Pharma, Inc. has higher upside potential than UroGen Pharma Ltd., analysts believe IGC Pharma, Inc. is more attractive than UroGen Pharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings URGNUroGen Pharma Ltd.6 1 0 IGCIGC Pharma, Inc.2 0 0 -
Is URGN or IGC More Risky?
UroGen Pharma Ltd. has a beta of 1.214, which suggesting that the stock is 21.395% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock URGN or IGC?
UroGen Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma Ltd. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios URGN or IGC?
UroGen Pharma Ltd. quarterly revenues are $27.5M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. UroGen Pharma Ltd.'s net income of -$33.3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, UroGen Pharma Ltd.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma Ltd. is 11.35x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income URGNUroGen Pharma Ltd.11.35x -- $27.5M -$33.3M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns URGN or MGTX?
MeiraGTx Holdings Plc has a net margin of -121.34% compared to UroGen Pharma Ltd.'s net margin of -12320.24%. UroGen Pharma Ltd.'s return on equity of -- beat MeiraGTx Holdings Plc's return on equity of -530.25%.
Company Gross Margin Earnings Per Share Invested Capital URGNUroGen Pharma Ltd.88.07% -$0.69 $14.5M MGTXMeiraGTx Holdings Plc-746.1% -$0.62 $47.5M -
What do Analysts Say About URGN or MGTX?
UroGen Pharma Ltd. has a consensus price target of $35.25, signalling upside risk potential of 53.06%. On the other hand MeiraGTx Holdings Plc has an analysts' consensus of $26.88 which suggests that it could grow by 237.2%. Given that MeiraGTx Holdings Plc has higher upside potential than UroGen Pharma Ltd., analysts believe MeiraGTx Holdings Plc is more attractive than UroGen Pharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings URGNUroGen Pharma Ltd.6 1 0 MGTXMeiraGTx Holdings Plc6 0 0 -
Is URGN or MGTX More Risky?
UroGen Pharma Ltd. has a beta of 1.214, which suggesting that the stock is 21.395% more volatile than S&P 500. In comparison MeiraGTx Holdings Plc has a beta of 1.384, suggesting its more volatile than the S&P 500 by 38.351%.
-
Which is a Better Dividend Stock URGN or MGTX?
UroGen Pharma Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MeiraGTx Holdings Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UroGen Pharma Ltd. pays -- of its earnings as a dividend. MeiraGTx Holdings Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios URGN or MGTX?
UroGen Pharma Ltd. quarterly revenues are $27.5M, which are larger than MeiraGTx Holdings Plc quarterly revenues of $410K. UroGen Pharma Ltd.'s net income of -$33.3M is higher than MeiraGTx Holdings Plc's net income of -$50.5M. Notably, UroGen Pharma Ltd.'s price-to-earnings ratio is -- while MeiraGTx Holdings Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UroGen Pharma Ltd. is 11.35x versus 23.18x for MeiraGTx Holdings Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income URGNUroGen Pharma Ltd.11.35x -- $27.5M -$33.3M MGTXMeiraGTx Holdings Plc23.18x -- $410K -$50.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
